Waldenström Macroglobulinemia
94
3
4
65
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
39 trials with published results (41%)
Research Maturity
65 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
21.3%
20 terminated out of 94 trials
76.5%
-10.0% vs benchmark
4%
4 trials in Phase 3/4
60%
39 of 65 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 65 completed trials
Clinical Trials (94)
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Ipilimumab and Local Radiation for Selected Solid Tumors
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia